NASDAQ:KYMR Kymera Therapeutics (KYMR) Stock Price, News & Analysis $80.65 +2.51 (+3.21%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$80.28 -0.37 (-0.46%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kymera Therapeutics Stock (NASDAQ:KYMR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kymera Therapeutics alerts:Sign Up Key Stats Today's Range$78.41▼$81.4250-Day Range$74.42▼$89.8752-Week Range$28.06▼$103.00Volume517,746 shsAverage Volume511,076 shsMarket Capitalization$6.63 billionP/E RatioN/ADividend YieldN/APrice Target$118.10Consensus RatingModerate Buy Company Overview Kymera Therapeutics, Inc. is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas. The company’s pipeline emphasizes immunology and oncology. Its lead program, a degrader targeting interleukin‐1 receptor–associated kinase 4 (IRAK4), is being evaluated for inflammatory and autoimmune diseases. In parallel, Kymera is advancing degraders against transcription factors and other intracellular targets implicated in hematologic malignancies. Preclinical efforts also include collaborations with global pharmaceutical partners to expand the application of its protein‐degradation technology to additional disease routes. Kymera operates research and development facilities in Massachusetts and maintains collaborations with academic institutions and biotech partners in North America and Europe. The company’s multi‐disciplinary team brings together expertise in structural biology, chemistry, pharmacology and clinical development. Since becoming a publicly traded company on the Nasdaq exchange under the ticker symbol KYMR, Kymera has continued to build its leadership bench to support late‐stage trials, regulatory interactions and future commercialization efforts. Rick Wagner serves as President and Chief Executive Officer, leading Kymera through its transition from a discovery‐focused entity to a clinical‐stage organization. Under his guidance, the company has expanded its internal capabilities and entered strategic research partnerships to accelerate the development of protein degraders. As Kymera progresses key programs into later‐stage clinical studies, it aims to validate targeted protein degradation as a new therapeutic modality that can address diseases with limited treatment options.AI Generated. May Contain Errors. Read More Kymera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreKYMR MarketRank™: Kymera Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 605th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingKymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 1 strong buy rating, 20 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialKymera Therapeutics has a consensus price target of $118.10, representing about 46.4% upside from its current price of $80.65.Amount of Analyst CoverageKymera Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kymera Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kymera Therapeutics are expected to decrease in the coming year, from ($3.34) to ($4.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kymera Therapeutics is -22.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kymera Therapeutics is -22.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKymera Therapeutics has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.02% of the float of Kymera Therapeutics has been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 18.84, which indicates bearish sentiment.Change versus previous monthShort interest in Kymera Therapeutics has recently increased by 0.68%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKymera Therapeutics does not currently pay a dividend.Dividend GrowthKymera Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.20 News SentimentKymera Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kymera Therapeutics this week, compared to 7 articles on an average week.Search Interest6 people have searched for KYMR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,454,902.00 in company stock.Percentage Held by Insiders15.98% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsKymera Therapeutics has minimal institutional ownership at this time.Read more about Kymera Therapeutics' insider trading history. Receive KYMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYMR Stock News HeadlinesKymera Therapeutics (KYMR) Valuation Check After New KT-621 And KT-579 Clinical And Preclinical ProgressMay 15, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Kiniksa Pharmaceuticals (KNSA), Kymera Therapeutics (KYMR)May 15, 2026 | theglobeandmail.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker. | Paradigm Press (Ad)Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society CongressesMay 15, 2026 | globenewswire.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 13, 2026 | americanbankingnews.comKymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comInsider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 3,000 Shares of StockMay 12, 2026 | insidertrades.comKymera Therapeutics (NASDAQ:KYMR) COO Sells $27,000.00 in StockApril 25, 2026 | insidertrades.comSee More Headlines KYMR Stock Analysis - Frequently Asked Questions How have KYMR shares performed this year? Kymera Therapeutics' stock was trading at $77.81 on January 1st, 2026. Since then, KYMR stock has increased by 3.6% and is now trading at $80.65. How were Kymera Therapeutics' earnings last quarter? Kymera Therapeutics, Inc. (NASDAQ:KYMR) released its quarterly earnings results on Thursday, April, 30th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics's revenue was up 55.5% on a year-over-year basis. Read the conference call transcript. When did Kymera Therapeutics IPO? Kymera Therapeutics (KYMR) raised $148 million in an IPO on Friday, August 21st 2020. The company issued 8,684,800 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO. Who are Kymera Therapeutics' major shareholders? Top institutional shareholders of Kymera Therapeutics include Atlas Venture Life Science Advisors LLC (5.57%), Siren L.L.C. (3.87%), Dimensional Fund Advisors LP (0.72%) and Jennison Associates LLC (0.62%). Insiders that own company stock include Bros Advisors Lp Baker, Venture Fund X LP Atlas, Bvf Partners L P/Il, Nello Mainolfi, Bruce N Jacobs, Jared Gollob, Ellen Chiniara, Jeremy G Chadwick, Noah Goodman, Bruce Booth, Elena Ridloff and Joanna Horobin. View institutional ownership trends. How do I buy shares of Kymera Therapeutics? Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kymera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kymera Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR). Company Calendar Last Earnings4/30/2026Today5/21/2026AGM 20266/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 KYMR's financial health is in the Green zone, according to TradeSmith. KYMR has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KYMR CIK1815442 Webwww.kymeratx.com Phone857-285-5300FaxN/AEmployees170Year Founded2017Price Target and Rating Average Price Target for Kymera Therapeutics$118.10 High Price Target$140.00 Low Price Target$90.00 Potential Upside/Downside+46.4%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$311.35 million Net Margins-611.94% Pretax Margin-611.94% Return on Equity-24.71% Return on Assets-22.05% Debt Debt-to-Equity RatioN/A Current Ratio10.81 Quick Ratio10.81 Sales & Book Value Annual Sales$39.21 million Price / Sales169.20 Cash FlowN/A Price / Cash FlowN/A Book Value$18.72 per share Price / Book4.31Miscellaneous Outstanding Shares82,260,000Free Float69,113,000Market Cap$6.63 billion OptionableOptionable Beta2.06 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:KYMR) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
